nodes	percent_of_prediction	percent_of_DWPC	metapath
Nortriptyline—PTGS1—esophageal cancer	0.661	1	CbGaD
Nortriptyline—Paresthesia of limbs—Methotrexate—esophageal cancer	0.00364	0.0394	CcSEcCtD
Nortriptyline—HTR2A—vagus nerve—esophageal cancer	0.00247	0.117	CbGeAlD
Nortriptyline—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.00219	0.0237	CcSEcCtD
Nortriptyline—Ileus paralytic—Capecitabine—esophageal cancer	0.00217	0.0235	CcSEcCtD
Nortriptyline—Loss of libido—Methotrexate—esophageal cancer	0.00151	0.0164	CcSEcCtD
Nortriptyline—CHRM3—exocrine gland—esophageal cancer	0.00143	0.0676	CbGeAlD
Nortriptyline—Appetite absent—Methotrexate—esophageal cancer	0.0014	0.0152	CcSEcCtD
Nortriptyline—Bone marrow depression—Capecitabine—esophageal cancer	0.00139	0.015	CcSEcCtD
Nortriptyline—Torsade de pointes—Capecitabine—esophageal cancer	0.00134	0.0145	CcSEcCtD
Nortriptyline—Throat sore—Capecitabine—esophageal cancer	0.0013	0.0141	CcSEcCtD
Nortriptyline—Tongue disorder—Capecitabine—esophageal cancer	0.00129	0.014	CcSEcCtD
Nortriptyline—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00129	0.014	CcSEcCtD
Nortriptyline—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00122	0.0133	CcSEcCtD
Nortriptyline—Body temperature increased—Carboplatin—esophageal cancer	0.00122	0.0132	CcSEcCtD
Nortriptyline—Tingling sensation—Capecitabine—esophageal cancer	0.00117	0.0126	CcSEcCtD
Nortriptyline—Petechiae—Capecitabine—esophageal cancer	0.00114	0.0123	CcSEcCtD
Nortriptyline—CHRM5—epithelium—esophageal cancer	0.00111	0.0526	CbGeAlD
Nortriptyline—Bone marrow depression—Methotrexate—esophageal cancer	0.00103	0.0112	CcSEcCtD
Nortriptyline—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00103	0.0112	CcSEcCtD
Nortriptyline—Nocturia—Capecitabine—esophageal cancer	0.00101	0.011	CcSEcCtD
Nortriptyline—ADRA1D—epithelium—esophageal cancer	0.000993	0.047	CbGeAlD
Nortriptyline—Coordination abnormal—Capecitabine—esophageal cancer	0.000954	0.0103	CcSEcCtD
Nortriptyline—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000941	0.0102	CcSEcCtD
Nortriptyline—Gingivitis—Methotrexate—esophageal cancer	0.000889	0.00963	CcSEcCtD
Nortriptyline—Irritability—Cisplatin—esophageal cancer	0.00088	0.00955	CcSEcCtD
Nortriptyline—Petechiae—Methotrexate—esophageal cancer	0.000848	0.00919	CcSEcCtD
Nortriptyline—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000843	0.00914	CcSEcCtD
Nortriptyline—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000778	0.00844	CcSEcCtD
Nortriptyline—Sweating increased—Cisplatin—esophageal cancer	0.000777	0.00842	CcSEcCtD
Nortriptyline—Vascular purpura—Capecitabine—esophageal cancer	0.00076	0.00824	CcSEcCtD
Nortriptyline—Pancytopenia—Cisplatin—esophageal cancer	0.000757	0.00821	CcSEcCtD
Nortriptyline—Eye pain—Capecitabine—esophageal cancer	0.000753	0.00817	CcSEcCtD
Nortriptyline—Libido decreased—Capecitabine—esophageal cancer	0.000733	0.00795	CcSEcCtD
Nortriptyline—Hot flush—Capecitabine—esophageal cancer	0.000727	0.00788	CcSEcCtD
Nortriptyline—Menopausal symptoms—Capecitabine—esophageal cancer	0.000721	0.00781	CcSEcCtD
Nortriptyline—Purpura—Capecitabine—esophageal cancer	0.000706	0.00765	CcSEcCtD
Nortriptyline—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000701	0.0076	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000697	0.00756	CcSEcCtD
Nortriptyline—Myocardial infarction—Cisplatin—esophageal cancer	0.000697	0.00756	CcSEcCtD
Nortriptyline—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000694	0.00752	CcSEcCtD
Nortriptyline—Stomatitis—Cisplatin—esophageal cancer	0.000693	0.00751	CcSEcCtD
Nortriptyline—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000675	0.00732	CcSEcCtD
Nortriptyline—Aplastic anaemia—Methotrexate—esophageal cancer	0.000655	0.0071	CcSEcCtD
Nortriptyline—Irritability—Capecitabine—esophageal cancer	0.000649	0.00704	CcSEcCtD
Nortriptyline—Urinary retention—Capecitabine—esophageal cancer	0.000647	0.00701	CcSEcCtD
Nortriptyline—Ataxia—Capecitabine—esophageal cancer	0.000639	0.00693	CcSEcCtD
Nortriptyline—Gynaecomastia—Methotrexate—esophageal cancer	0.000624	0.00677	CcSEcCtD
Nortriptyline—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000621	0.00673	CcSEcCtD
Nortriptyline—CHRM1—trachea—esophageal cancer	0.000614	0.029	CbGeAlD
Nortriptyline—CHRM3—smooth muscle tissue—esophageal cancer	0.000599	0.0283	CbGeAlD
Nortriptyline—Eye disorder—Cisplatin—esophageal cancer	0.000596	0.00647	CcSEcCtD
Nortriptyline—Tinnitus—Cisplatin—esophageal cancer	0.000595	0.00645	CcSEcCtD
Nortriptyline—Flushing—Cisplatin—esophageal cancer	0.000592	0.00642	CcSEcCtD
Nortriptyline—Sweating increased—Capecitabine—esophageal cancer	0.000573	0.00621	CcSEcCtD
Nortriptyline—ADRA1A—epithelium—esophageal cancer	0.000571	0.027	CbGeAlD
Nortriptyline—Arrhythmia—Cisplatin—esophageal cancer	0.00057	0.00618	CcSEcCtD
Nortriptyline—Alopecia—Cisplatin—esophageal cancer	0.000564	0.00611	CcSEcCtD
Nortriptyline—Pancytopenia—Capecitabine—esophageal cancer	0.000558	0.00605	CcSEcCtD
Nortriptyline—HTR2A—neck—esophageal cancer	0.000542	0.0256	CbGeAlD
Nortriptyline—Weight increased—Capecitabine—esophageal cancer	0.000535	0.0058	CcSEcCtD
Nortriptyline—Weight decreased—Capecitabine—esophageal cancer	0.000532	0.00577	CcSEcCtD
Nortriptyline—SLC6A4—digestive system—esophageal cancer	0.00053	0.0251	CbGeAlD
Nortriptyline—Vision blurred—Cisplatin—esophageal cancer	0.000524	0.00568	CcSEcCtD
Nortriptyline—Tremor—Cisplatin—esophageal cancer	0.00052	0.00564	CcSEcCtD
Nortriptyline—ORM1—lung—esophageal cancer	0.00052	0.0246	CbGeAlD
Nortriptyline—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000517	0.0056	CcSEcCtD
Nortriptyline—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000517	0.0056	CcSEcCtD
Nortriptyline—Ill-defined disorder—Cisplatin—esophageal cancer	0.000515	0.00559	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000514	0.00557	CcSEcCtD
Nortriptyline—Myocardial infarction—Capecitabine—esophageal cancer	0.000514	0.00557	CcSEcCtD
Nortriptyline—Stomatitis—Capecitabine—esophageal cancer	0.000511	0.00554	CcSEcCtD
Nortriptyline—Jaundice—Capecitabine—esophageal cancer	0.000511	0.00554	CcSEcCtD
Nortriptyline—Malaise—Cisplatin—esophageal cancer	0.000501	0.00543	CcSEcCtD
Nortriptyline—Leukopenia—Cisplatin—esophageal cancer	0.000497	0.00539	CcSEcCtD
Nortriptyline—Agranulocytosis—Capecitabine—esophageal cancer	0.000489	0.0053	CcSEcCtD
Nortriptyline—Irritability—Methotrexate—esophageal cancer	0.000483	0.00524	CcSEcCtD
Nortriptyline—Convulsion—Cisplatin—esophageal cancer	0.000481	0.00522	CcSEcCtD
Nortriptyline—Ataxia—Methotrexate—esophageal cancer	0.000476	0.00516	CcSEcCtD
Nortriptyline—CHRM3—digestive system—esophageal cancer	0.000473	0.0224	CbGeAlD
Nortriptyline—Anxiety—Cisplatin—esophageal cancer	0.000471	0.00511	CcSEcCtD
Nortriptyline—Hepatitis—Capecitabine—esophageal cancer	0.00047	0.0051	CcSEcCtD
Nortriptyline—Hypoaesthesia—Capecitabine—esophageal cancer	0.000468	0.00508	CcSEcCtD
Nortriptyline—Discomfort—Cisplatin—esophageal cancer	0.000467	0.00507	CcSEcCtD
Nortriptyline—Oedema peripheral—Capecitabine—esophageal cancer	0.000463	0.00503	CcSEcCtD
Nortriptyline—Oedema—Cisplatin—esophageal cancer	0.000453	0.00492	CcSEcCtD
Nortriptyline—Thrombocytopenia—Cisplatin—esophageal cancer	0.000444	0.00481	CcSEcCtD
Nortriptyline—SLC6A4—lung—esophageal cancer	0.000443	0.021	CbGeAlD
Nortriptyline—Tachycardia—Cisplatin—esophageal cancer	0.000443	0.0048	CcSEcCtD
Nortriptyline—HRH1—epithelium—esophageal cancer	0.000442	0.0209	CbGeAlD
Nortriptyline—CHRM1—lung—esophageal cancer	0.000441	0.0209	CbGeAlD
Nortriptyline—Eye disorder—Capecitabine—esophageal cancer	0.00044	0.00477	CcSEcCtD
Nortriptyline—CYP2C19—digestive system—esophageal cancer	0.000439	0.0208	CbGeAlD
Nortriptyline—Tinnitus—Capecitabine—esophageal cancer	0.000439	0.00476	CcSEcCtD
Nortriptyline—Hyperhidrosis—Cisplatin—esophageal cancer	0.000438	0.00475	CcSEcCtD
Nortriptyline—Flushing—Capecitabine—esophageal cancer	0.000437	0.00473	CcSEcCtD
Nortriptyline—Eosinophilia—Methotrexate—esophageal cancer	0.000433	0.0047	CcSEcCtD
Nortriptyline—Anorexia—Cisplatin—esophageal cancer	0.000432	0.00469	CcSEcCtD
Nortriptyline—Protriptyline—ABCB1—esophageal cancer	0.00043	0.18	CrCbGaD
Nortriptyline—HRH1—smooth muscle tissue—esophageal cancer	0.000426	0.0201	CbGeAlD
Nortriptyline—Hypotension—Cisplatin—esophageal cancer	0.000424	0.00459	CcSEcCtD
Nortriptyline—Arrhythmia—Capecitabine—esophageal cancer	0.00042	0.00456	CcSEcCtD
Nortriptyline—Alopecia—Capecitabine—esophageal cancer	0.000416	0.00451	CcSEcCtD
Nortriptyline—Pancytopenia—Methotrexate—esophageal cancer	0.000416	0.00451	CcSEcCtD
Nortriptyline—PTGS1—epithelium—esophageal cancer	0.000409	0.0193	CbGeAlD
Nortriptyline—Paraesthesia—Cisplatin—esophageal cancer	0.000407	0.00441	CcSEcCtD
Nortriptyline—Erectile dysfunction—Methotrexate—esophageal cancer	0.000403	0.00437	CcSEcCtD
Nortriptyline—Dysgeusia—Capecitabine—esophageal cancer	0.000401	0.00435	CcSEcCtD
Nortriptyline—Decreased appetite—Cisplatin—esophageal cancer	0.000394	0.00427	CcSEcCtD
Nortriptyline—PTGS1—smooth muscle tissue—esophageal cancer	0.000394	0.0186	CbGeAlD
Nortriptyline—HRH1—trachea—esophageal cancer	0.000391	0.0185	CbGeAlD
Nortriptyline—Drowsiness—Methotrexate—esophageal cancer	0.00039	0.00423	CcSEcCtD
Nortriptyline—SLC6A2—lung—esophageal cancer	0.00039	0.0184	CbGeAlD
Nortriptyline—Vision blurred—Capecitabine—esophageal cancer	0.000386	0.00418	CcSEcCtD
Nortriptyline—Tremor—Capecitabine—esophageal cancer	0.000384	0.00416	CcSEcCtD
Nortriptyline—Stomatitis—Methotrexate—esophageal cancer	0.00038	0.00412	CcSEcCtD
Nortriptyline—Ill-defined disorder—Capecitabine—esophageal cancer	0.00038	0.00412	CcSEcCtD
Nortriptyline—Sweating—Methotrexate—esophageal cancer	0.000374	0.00406	CcSEcCtD
Nortriptyline—Feeling abnormal—Cisplatin—esophageal cancer	0.000374	0.00405	CcSEcCtD
Nortriptyline—Malaise—Capecitabine—esophageal cancer	0.000369	0.004	CcSEcCtD
Nortriptyline—HTR2A—epithelium—esophageal cancer	0.000369	0.0174	CbGeAlD
Nortriptyline—Syncope—Capecitabine—esophageal cancer	0.000367	0.00398	CcSEcCtD
Nortriptyline—Leukopenia—Capecitabine—esophageal cancer	0.000367	0.00397	CcSEcCtD
Nortriptyline—Desipramine—CYP2A6—esophageal cancer	0.000364	0.152	CrCbGaD
Nortriptyline—Agranulocytosis—Methotrexate—esophageal cancer	0.000364	0.00395	CcSEcCtD
Nortriptyline—Palpitations—Capecitabine—esophageal cancer	0.000362	0.00392	CcSEcCtD
Nortriptyline—PTGS1—trachea—esophageal cancer	0.000361	0.0171	CbGeAlD
Nortriptyline—Loss of consciousness—Capecitabine—esophageal cancer	0.00036	0.0039	CcSEcCtD
Nortriptyline—CYP1A2—digestive system—esophageal cancer	0.000359	0.017	CbGeAlD
Nortriptyline—Body temperature increased—Cisplatin—esophageal cancer	0.000358	0.00389	CcSEcCtD
Nortriptyline—ORM1—lymph node—esophageal cancer	0.000355	0.0168	CbGeAlD
Nortriptyline—HTR2A—smooth muscle tissue—esophageal cancer	0.000355	0.0168	CbGeAlD
Nortriptyline—DRD2—lung—esophageal cancer	0.000355	0.0168	CbGeAlD
Nortriptyline—Hypertension—Capecitabine—esophageal cancer	0.000354	0.00383	CcSEcCtD
Nortriptyline—Hepatitis—Methotrexate—esophageal cancer	0.00035	0.0038	CcSEcCtD
Nortriptyline—Anxiety—Capecitabine—esophageal cancer	0.000347	0.00377	CcSEcCtD
Nortriptyline—CYP3A5—digestive system—esophageal cancer	0.000346	0.0164	CbGeAlD
Nortriptyline—Discomfort—Capecitabine—esophageal cancer	0.000344	0.00374	CcSEcCtD
Nortriptyline—Dry mouth—Capecitabine—esophageal cancer	0.000341	0.0037	CcSEcCtD
Nortriptyline—CYP2C9—digestive system—esophageal cancer	0.000341	0.0161	CbGeAlD
Nortriptyline—Confusional state—Capecitabine—esophageal cancer	0.000337	0.00365	CcSEcCtD
Nortriptyline—HRH1—digestive system—esophageal cancer	0.000336	0.0159	CbGeAlD
Nortriptyline—Oedema—Capecitabine—esophageal cancer	0.000334	0.00362	CcSEcCtD
Nortriptyline—Hypersensitivity—Cisplatin—esophageal cancer	0.000334	0.00362	CcSEcCtD
Nortriptyline—Shock—Capecitabine—esophageal cancer	0.000329	0.00357	CcSEcCtD
Nortriptyline—Eye disorder—Methotrexate—esophageal cancer	0.000327	0.00355	CcSEcCtD
Nortriptyline—Thrombocytopenia—Capecitabine—esophageal cancer	0.000327	0.00355	CcSEcCtD
Nortriptyline—Tinnitus—Methotrexate—esophageal cancer	0.000327	0.00354	CcSEcCtD
Nortriptyline—Tachycardia—Capecitabine—esophageal cancer	0.000326	0.00354	CcSEcCtD
Nortriptyline—HTR2A—trachea—esophageal cancer	0.000326	0.0154	CbGeAlD
Nortriptyline—Asthenia—Cisplatin—esophageal cancer	0.000325	0.00353	CcSEcCtD
Nortriptyline—Hyperhidrosis—Capecitabine—esophageal cancer	0.000323	0.0035	CcSEcCtD
Nortriptyline—CYP2E1—digestive system—esophageal cancer	0.000323	0.0153	CbGeAlD
Nortriptyline—Anorexia—Capecitabine—esophageal cancer	0.000319	0.00345	CcSEcCtD
Nortriptyline—Epinastine—ABCB1—esophageal cancer	0.000318	0.133	CrCbGaD
Nortriptyline—Hypotension—Capecitabine—esophageal cancer	0.000312	0.00339	CcSEcCtD
Nortriptyline—ALB—lymph node—esophageal cancer	0.000312	0.0147	CbGeAlD
Nortriptyline—PTGS1—digestive system—esophageal cancer	0.000311	0.0147	CbGeAlD
Nortriptyline—Diarrhoea—Cisplatin—esophageal cancer	0.00031	0.00336	CcSEcCtD
Nortriptyline—Alopecia—Methotrexate—esophageal cancer	0.000309	0.00336	CcSEcCtD
Nortriptyline—Insomnia—Capecitabine—esophageal cancer	0.000302	0.00328	CcSEcCtD
Nortriptyline—Paraesthesia—Capecitabine—esophageal cancer	0.0003	0.00325	CcSEcCtD
Nortriptyline—CYP1A2—lung—esophageal cancer	0.0003	0.0142	CbGeAlD
Nortriptyline—Dysgeusia—Methotrexate—esophageal cancer	0.000299	0.00324	CcSEcCtD
Nortriptyline—Dyspepsia—Capecitabine—esophageal cancer	0.000294	0.00319	CcSEcCtD
Nortriptyline—Decreased appetite—Capecitabine—esophageal cancer	0.000291	0.00315	CcSEcCtD
Nortriptyline—CYP3A5—lung—esophageal cancer	0.000289	0.0137	CbGeAlD
Nortriptyline—Vomiting—Cisplatin—esophageal cancer	0.000288	0.00313	CcSEcCtD
Nortriptyline—Fatigue—Capecitabine—esophageal cancer	0.000288	0.00312	CcSEcCtD
Nortriptyline—Vision blurred—Methotrexate—esophageal cancer	0.000287	0.00312	CcSEcCtD
Nortriptyline—Rash—Cisplatin—esophageal cancer	0.000286	0.0031	CcSEcCtD
Nortriptyline—Constipation—Capecitabine—esophageal cancer	0.000286	0.0031	CcSEcCtD
Nortriptyline—Dermatitis—Cisplatin—esophageal cancer	0.000286	0.0031	CcSEcCtD
Nortriptyline—Ill-defined disorder—Methotrexate—esophageal cancer	0.000283	0.00307	CcSEcCtD
Nortriptyline—HTR2A—digestive system—esophageal cancer	0.000281	0.0133	CbGeAlD
Nortriptyline—HRH1—lung—esophageal cancer	0.000281	0.0133	CbGeAlD
Nortriptyline—Feeling abnormal—Capecitabine—esophageal cancer	0.000275	0.00299	CcSEcCtD
Nortriptyline—Malaise—Methotrexate—esophageal cancer	0.000275	0.00298	CcSEcCtD
Nortriptyline—Maprotiline—ABCB1—esophageal cancer	0.000274	0.115	CrCbGaD
Nortriptyline—Leukopenia—Methotrexate—esophageal cancer	0.000273	0.00296	CcSEcCtD
Nortriptyline—CYP2E1—lung—esophageal cancer	0.00027	0.0128	CbGeAlD
Nortriptyline—Nausea—Cisplatin—esophageal cancer	0.000269	0.00292	CcSEcCtD
Nortriptyline—SLC6A2—lymph node—esophageal cancer	0.000267	0.0126	CbGeAlD
Nortriptyline—Urticaria—Capecitabine—esophageal cancer	0.000266	0.00288	CcSEcCtD
Nortriptyline—Abdominal pain—Capecitabine—esophageal cancer	0.000264	0.00286	CcSEcCtD
Nortriptyline—Body temperature increased—Capecitabine—esophageal cancer	0.000264	0.00286	CcSEcCtD
Nortriptyline—Convulsion—Methotrexate—esophageal cancer	0.000264	0.00286	CcSEcCtD
Nortriptyline—CYP3A4—digestive system—esophageal cancer	0.00026	0.0123	CbGeAlD
Nortriptyline—PTGS1—lung—esophageal cancer	0.00026	0.0123	CbGeAlD
Nortriptyline—Discomfort—Methotrexate—esophageal cancer	0.000256	0.00278	CcSEcCtD
Nortriptyline—CYP2D6—digestive system—esophageal cancer	0.000256	0.0121	CbGeAlD
Nortriptyline—Confusional state—Methotrexate—esophageal cancer	0.000251	0.00272	CcSEcCtD
Nortriptyline—Hypersensitivity—Capecitabine—esophageal cancer	0.000246	0.00267	CcSEcCtD
Nortriptyline—Thrombocytopenia—Methotrexate—esophageal cancer	0.000244	0.00264	CcSEcCtD
Nortriptyline—Hyperhidrosis—Methotrexate—esophageal cancer	0.000241	0.00261	CcSEcCtD
Nortriptyline—Asthenia—Capecitabine—esophageal cancer	0.00024	0.0026	CcSEcCtD
Nortriptyline—Anorexia—Methotrexate—esophageal cancer	0.000237	0.00257	CcSEcCtD
Nortriptyline—Pruritus—Capecitabine—esophageal cancer	0.000236	0.00256	CcSEcCtD
Nortriptyline—HTR2A—lung—esophageal cancer	0.000234	0.0111	CbGeAlD
Nortriptyline—Hypotension—Methotrexate—esophageal cancer	0.000232	0.00252	CcSEcCtD
Nortriptyline—Diarrhoea—Capecitabine—esophageal cancer	0.000229	0.00248	CcSEcCtD
Nortriptyline—Insomnia—Methotrexate—esophageal cancer	0.000225	0.00244	CcSEcCtD
Nortriptyline—Paraesthesia—Methotrexate—esophageal cancer	0.000223	0.00242	CcSEcCtD
Nortriptyline—Somnolence—Methotrexate—esophageal cancer	0.000221	0.0024	CcSEcCtD
Nortriptyline—Dizziness—Capecitabine—esophageal cancer	0.000221	0.0024	CcSEcCtD
Nortriptyline—Dyspepsia—Methotrexate—esophageal cancer	0.000219	0.00237	CcSEcCtD
Nortriptyline—Decreased appetite—Methotrexate—esophageal cancer	0.000216	0.00235	CcSEcCtD
Nortriptyline—Fatigue—Methotrexate—esophageal cancer	0.000215	0.00233	CcSEcCtD
Nortriptyline—Vomiting—Capecitabine—esophageal cancer	0.000213	0.0023	CcSEcCtD
Nortriptyline—Rash—Capecitabine—esophageal cancer	0.000211	0.00229	CcSEcCtD
Nortriptyline—Dermatitis—Capecitabine—esophageal cancer	0.000211	0.00228	CcSEcCtD
Nortriptyline—Headache—Capecitabine—esophageal cancer	0.000209	0.00227	CcSEcCtD
Nortriptyline—Feeling abnormal—Methotrexate—esophageal cancer	0.000205	0.00222	CcSEcCtD
Nortriptyline—Nausea—Capecitabine—esophageal cancer	0.000199	0.00215	CcSEcCtD
Nortriptyline—Urticaria—Methotrexate—esophageal cancer	0.000198	0.00214	CcSEcCtD
Nortriptyline—Abdominal pain—Methotrexate—esophageal cancer	0.000197	0.00213	CcSEcCtD
Nortriptyline—Body temperature increased—Methotrexate—esophageal cancer	0.000197	0.00213	CcSEcCtD
Nortriptyline—HRH1—lymph node—esophageal cancer	0.000192	0.00908	CbGeAlD
Nortriptyline—Hypersensitivity—Methotrexate—esophageal cancer	0.000183	0.00199	CcSEcCtD
Nortriptyline—Asthenia—Methotrexate—esophageal cancer	0.000179	0.00194	CcSEcCtD
Nortriptyline—PTGS1—lymph node—esophageal cancer	0.000178	0.0084	CbGeAlD
Nortriptyline—Pruritus—Methotrexate—esophageal cancer	0.000176	0.00191	CcSEcCtD
Nortriptyline—Diarrhoea—Methotrexate—esophageal cancer	0.00017	0.00185	CcSEcCtD
Nortriptyline—Clomipramine—ABCB1—esophageal cancer	0.000168	0.0705	CrCbGaD
Nortriptyline—Chlorprothixene—ABCB1—esophageal cancer	0.000168	0.0702	CrCbGaD
Nortriptyline—Dizziness—Methotrexate—esophageal cancer	0.000165	0.00178	CcSEcCtD
Nortriptyline—Vomiting—Methotrexate—esophageal cancer	0.000158	0.00172	CcSEcCtD
Nortriptyline—Rash—Methotrexate—esophageal cancer	0.000157	0.0017	CcSEcCtD
Nortriptyline—Dermatitis—Methotrexate—esophageal cancer	0.000157	0.0017	CcSEcCtD
Nortriptyline—Headache—Methotrexate—esophageal cancer	0.000156	0.00169	CcSEcCtD
Nortriptyline—Trimipramine—ABCB1—esophageal cancer	0.000155	0.0649	CrCbGaD
Nortriptyline—Nausea—Methotrexate—esophageal cancer	0.000148	0.0016	CcSEcCtD
Nortriptyline—Doxepin—ABCB1—esophageal cancer	0.000148	0.0618	CrCbGaD
Nortriptyline—Desipramine—ABCB1—esophageal cancer	0.000136	0.0567	CrCbGaD
Nortriptyline—Imipramine—ABCB1—esophageal cancer	0.000115	0.0481	CrCbGaD
Nortriptyline—Amitriptyline—ABCB1—esophageal cancer	0.000114	0.0478	CrCbGaD
Nortriptyline—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.16e-05	5.19e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—KDR—esophageal cancer	1.15e-05	5.16e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—KDR—esophageal cancer	1.15e-05	5.15e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—KDR—esophageal cancer	1.14e-05	5.13e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—KDR—esophageal cancer	1.14e-05	5.11e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	1.14e-05	5.1e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—CCND1—esophageal cancer	1.14e-05	5.1e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.13e-05	5.08e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	1.13e-05	5.07e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—KDR—esophageal cancer	1.13e-05	5.06e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—KDR—esophageal cancer	1.13e-05	5.05e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	1.12e-05	5.01e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling by GPCR—PIK3CA—esophageal cancer	1.11e-05	4.99e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	1.11e-05	4.98e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	1.1e-05	4.94e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	1.1e-05	4.93e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—ERBB2—esophageal cancer	1.09e-05	4.9e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.09e-05	4.89e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.09e-05	4.87e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.09e-05	4.86e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	1.08e-05	4.86e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	1.08e-05	4.86e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	1.08e-05	4.85e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	1.08e-05	4.83e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.08e-05	4.83e-05	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—PTGS2—esophageal cancer	1.08e-05	4.82e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	1.07e-05	4.82e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—CCND1—esophageal cancer	1.07e-05	4.81e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.07e-05	4.81e-05	CbGpPWpGaD
Nortriptyline—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.07e-05	4.79e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	1.06e-05	4.77e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	1.06e-05	4.77e-05	CbGpPWpGaD
Nortriptyline—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.06e-05	4.76e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	1.06e-05	4.76e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.06e-05	4.73e-05	CbGpPWpGaD
Nortriptyline—ALB—Hemostasis—PIK3CA—esophageal cancer	1.05e-05	4.7e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—EP300—esophageal cancer	1.05e-05	4.69e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—NOS3—esophageal cancer	1.04e-05	4.68e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.04e-05	4.67e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.04e-05	4.66e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—CDKN1A—esophageal cancer	1.04e-05	4.65e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.03e-05	4.63e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—CCND1—esophageal cancer	1.03e-05	4.6e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.03e-05	4.6e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.02e-05	4.56e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.02e-05	4.56e-05	CbGpPWpGaD
Nortriptyline—ALB—Hemostasis—TP53—esophageal cancer	1.01e-05	4.55e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.01e-05	4.54e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.01e-05	4.52e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CREBBP—esophageal cancer	9.99e-06	4.48e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	9.94e-06	4.45e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—EP300—esophageal cancer	9.88e-06	4.42e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	9.83e-06	4.4e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—CREBBP—esophageal cancer	9.82e-06	4.4e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—EGFR—esophageal cancer	9.82e-06	4.4e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CREBBP—esophageal cancer	9.81e-06	4.39e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—CREBBP—esophageal cancer	9.8e-06	4.39e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	9.78e-06	4.38e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	9.75e-06	4.37e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—ENO1—esophageal cancer	9.74e-06	4.36e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.74e-06	4.36e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	9.7e-06	4.35e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	9.7e-06	4.35e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	9.66e-06	4.33e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	9.66e-06	4.33e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	9.65e-06	4.33e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	9.65e-06	4.32e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—EGFR—esophageal cancer	9.64e-06	4.32e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	9.63e-06	4.31e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	9.61e-06	4.3e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PSME2—esophageal cancer	9.59e-06	4.3e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PSME1—esophageal cancer	9.59e-06	4.3e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	9.58e-06	4.29e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.55e-06	4.28e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—PTGS2—esophageal cancer	9.55e-06	4.28e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	9.53e-06	4.27e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	9.48e-06	4.25e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	9.48e-06	4.25e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	9.46e-06	4.24e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—EP300—esophageal cancer	9.46e-06	4.24e-05	CbGpPWpGaD
Nortriptyline—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	9.38e-06	4.2e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	9.35e-06	4.19e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	9.24e-06	4.14e-05	CbGpPWpGaD
Nortriptyline—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	9.23e-06	4.14e-05	CbGpPWpGaD
Nortriptyline—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	9.21e-06	4.13e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—HMOX1—esophageal cancer	9.2e-06	4.12e-05	CbGpPWpGaD
Nortriptyline—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	9.18e-06	4.11e-05	CbGpPWpGaD
Nortriptyline—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	9.15e-06	4.1e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—MYC—esophageal cancer	9.12e-06	4.09e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	9.08e-06	4.07e-05	CbGpPWpGaD
Nortriptyline—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	9.06e-06	4.06e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	9.04e-06	4.05e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.03e-06	4.05e-05	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—EP300—esophageal cancer	8.95e-06	4.01e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—NOS3—esophageal cancer	8.94e-06	4.01e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—EGFR—esophageal cancer	8.92e-06	4e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—EP300—esophageal cancer	8.89e-06	3.98e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—ABCB1—esophageal cancer	8.83e-06	3.96e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—NOS3—esophageal cancer	8.8e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—NOS3—esophageal cancer	8.79e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—NOS3—esophageal cancer	8.78e-06	3.94e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—NOS3—esophageal cancer	8.78e-06	3.93e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—NOS3—esophageal cancer	8.75e-06	3.92e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—NOS3—esophageal cancer	8.73e-06	3.91e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—NOS3—esophageal cancer	8.64e-06	3.87e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	8.62e-06	3.86e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—MYC—esophageal cancer	8.61e-06	3.86e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.57e-06	3.84e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	8.52e-06	3.82e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—CREBBP—esophageal cancer	8.44e-06	3.78e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—CCND1—esophageal cancer	8.42e-06	3.77e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—EGFR—esophageal cancer	8.42e-06	3.77e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	8.38e-06	3.76e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—CCND1—esophageal cancer	8.38e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—ERBB2—esophageal cancer	8.37e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	8.37e-06	3.75e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	8.34e-06	3.74e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	8.31e-06	3.72e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.28e-06	3.71e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—MYC—esophageal cancer	8.24e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	8.23e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	8.23e-06	3.69e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—ERBB2—esophageal cancer	8.21e-06	3.68e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	8.21e-06	3.68e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	8.19e-06	3.67e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	8.16e-06	3.66e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	8.14e-06	3.65e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	8.1e-06	3.63e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	8.08e-06	3.62e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	8.06e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—EGFR—esophageal cancer	8.06e-06	3.61e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PTGS2—esophageal cancer	8.04e-06	3.6e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PTGS2—esophageal cancer	8.03e-06	3.6e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	8.02e-06	3.59e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—EP300—esophageal cancer	7.94e-06	3.56e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.82e-06	3.5e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.78e-06	3.49e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	7.76e-06	3.48e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—EP300—esophageal cancer	7.75e-06	3.47e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—MYC—esophageal cancer	7.75e-06	3.47e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	7.74e-06	3.47e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—EP300—esophageal cancer	7.71e-06	3.45e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	7.58e-06	3.4e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—CREBBP—esophageal cancer	7.58e-06	3.4e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—NOS3—esophageal cancer	7.56e-06	3.39e-05	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—TP53—esophageal cancer	7.49e-06	3.36e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CCND1—esophageal cancer	7.39e-06	3.31e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—EP300—esophageal cancer	7.38e-06	3.31e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	7.31e-06	3.27e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CCND1—esophageal cancer	7.27e-06	3.26e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CCND1—esophageal cancer	7.26e-06	3.25e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CCND1—esophageal cancer	7.23e-06	3.24e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CCND1—esophageal cancer	7.21e-06	3.23e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	7.15e-06	3.2e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CCND1—esophageal cancer	7.14e-06	3.2e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	7.12e-06	3.19e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.1e-06	3.18e-05	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—TP53—esophageal cancer	7.07e-06	3.17e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	7.04e-06	3.15e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	7.02e-06	3.15e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	7e-06	3.14e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	7e-06	3.13e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	6.98e-06	3.13e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—CREBBP—esophageal cancer	6.97e-06	3.12e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PTGS2—esophageal cancer	6.91e-06	3.1e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—CREBBP—esophageal cancer	6.91e-06	3.1e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	6.91e-06	3.1e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	6.89e-06	3.09e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.82e-06	3.05e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—EP300—esophageal cancer	6.8e-06	3.05e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—NOS3—esophageal cancer	6.78e-06	3.04e-05	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—TP53—esophageal cancer	6.77e-06	3.03e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—MYC—esophageal cancer	6.75e-06	3.03e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—MYC—esophageal cancer	6.72e-06	3.01e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—EP300—esophageal cancer	6.7e-06	3e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—EP300—esophageal cancer	6.69e-06	3e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—EP300—esophageal cancer	6.68e-06	2.99e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.68e-06	2.99e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—EP300—esophageal cancer	6.68e-06	2.99e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—EP300—esophageal cancer	6.66e-06	2.98e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—EP300—esophageal cancer	6.64e-06	2.97e-05	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—PIK3CA—esophageal cancer	6.62e-06	2.97e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—EGFR—esophageal cancer	6.61e-06	2.96e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	6.58e-06	2.95e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—EP300—esophageal cancer	6.57e-06	2.95e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—EGFR—esophageal cancer	6.57e-06	2.94e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—EP300—esophageal cancer	6.56e-06	2.94e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—MYC—esophageal cancer	6.43e-06	2.88e-05	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—TP53—esophageal cancer	6.36e-06	2.85e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	6.29e-06	2.82e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—NOS3—esophageal cancer	6.24e-06	2.8e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PTGS2—esophageal cancer	6.21e-06	2.78e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—NOS3—esophageal cancer	6.19e-06	2.77e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—MYC—esophageal cancer	5.93e-06	2.66e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—CREBBP—esophageal cancer	5.9e-06	2.65e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—PIK3CA—esophageal cancer	5.87e-06	2.63e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—MYC—esophageal cancer	5.83e-06	2.61e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—MYC—esophageal cancer	5.82e-06	2.61e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—MYC—esophageal cancer	5.8e-06	2.6e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—EGFR—esophageal cancer	5.8e-06	2.6e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—MYC—esophageal cancer	5.78e-06	2.59e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—EP300—esophageal cancer	5.75e-06	2.58e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	5.73e-06	2.57e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—MYC—esophageal cancer	5.73e-06	2.57e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—MYC—esophageal cancer	5.71e-06	2.56e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PTGS2—esophageal cancer	5.71e-06	2.56e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—EGFR—esophageal cancer	5.71e-06	2.56e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	5.7e-06	2.56e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—EGFR—esophageal cancer	5.69e-06	2.55e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—EGFR—esophageal cancer	5.68e-06	2.54e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PTGS2—esophageal cancer	5.66e-06	2.54e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—EGFR—esophageal cancer	5.66e-06	2.53e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—EGFR—esophageal cancer	5.6e-06	2.51e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	5.59e-06	2.5e-05	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—TP53—esophageal cancer	5.55e-06	2.48e-05	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—TP53—esophageal cancer	5.52e-06	2.47e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	5.46e-06	2.45e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—NOS3—esophageal cancer	5.29e-06	2.37e-05	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—TP53—esophageal cancer	5.28e-06	2.37e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—EP300—esophageal cancer	5.16e-06	2.31e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	5.03e-06	2.26e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	4.95e-06	2.22e-05	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PIK3CA—esophageal cancer	4.95e-06	2.22e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	4.94e-06	2.21e-05	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PIK3CA—esophageal cancer	4.94e-06	2.21e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	4.93e-06	2.21e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	4.91e-06	2.2e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—TP53—esophageal cancer	4.87e-06	2.18e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	4.86e-06	2.18e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	4.85e-06	2.17e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PTGS2—esophageal cancer	4.83e-06	2.17e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—TP53—esophageal cancer	4.79e-06	2.15e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—TP53—esophageal cancer	4.78e-06	2.14e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—TP53—esophageal cancer	4.77e-06	2.14e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—TP53—esophageal cancer	4.75e-06	2.13e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—EP300—esophageal cancer	4.75e-06	2.13e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—EP300—esophageal cancer	4.71e-06	2.11e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—TP53—esophageal cancer	4.7e-06	2.11e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—TP53—esophageal cancer	4.69e-06	2.1e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.56e-06	2.04e-05	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PIK3CA—esophageal cancer	4.25e-06	1.91e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—NOS3—esophageal cancer	4.08e-06	1.83e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—EP300—esophageal cancer	4.02e-06	1.8e-05	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PIK3CA—esophageal cancer	3.82e-06	1.71e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.73e-06	1.67e-05	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.51e-06	1.57e-05	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PIK3CA—esophageal cancer	3.48e-06	1.56e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—EP300—esophageal cancer	3.1e-06	1.39e-05	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.97e-06	1.33e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.3e-06	1.03e-05	CbGpPWpGaD
